Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Determining Safety and Maximum Tolerated Dose (MTD) of Anti-BCMA CAR-NK Therapy in Relapsed or Refractory Multiple Myeloma

NCT06242249 is registered in ClinicalTrials.gov with Shahid Beheshti University of Medical Sciences as lead sponsor.

NCT NCT06242249
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06242249 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Determining Safety and Maximum Tolerated Dose (MTD) of Anti-BCMA CAR-NK Therapy in Relapsed or Refractory Multiple Myeloma
Lead sponsor
Shahid Beheshti University of Medical Sciences
Phase
Phase 1/2
Overall status
Unknown status
Start date
April 30, 2024
Completion date
June 30, 2026
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma, refractory